Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis
NCT00617643 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2010-12-06
Summary
Triomune is the most commonly prescribed treatment for HIV infection in Uganda. Triomune is manufactured by a generic drug company and consists of three drugs combined in a single pill given twice daily (stavudine 30mg plus lamivudine 150mg plus nevirapine 200mg).
It is known that the levels of nevirapine in a patient's blood are highest in the first two weeks of treatment. Therefore it is recommended that patients starting on nevirapine should undergo dose escalation i.e start on 200mg once daily for two weeks and then increase to full dose of 200mg twice daily in order to avoid nevirapine related rash. It is not possible to do dose escalation with a fixed dose combination pill like Triomune and for the two weeks of the dose escalation patients either can buy stavudine plus lamivudine plus nevirapine as separate pills or take Triomune in the morning and then take stavudine plus lamivudine as separate pills in the evening.
Rifampicin is used to treat TB and lowers the levels of nevirapine in a patient's blood. This raises two questions in routine clinical practice for patients who are co-infected with HIV and TB (1) Do we need to put our patients to the trouble of dose escalation of nevirapine if they are already on rifampicin? and (2) If we dose escalate nevirapine in patients on rifampicin, are we putting them at risk of low drug levels and development of resistance? The aim of this study is to compare the plasma concentrations of nevirapine in HIV infected patients who are commencing antiretroviral therapy with and without a lead in dose of nevirapine and who are also receiving concomitant treatment with antituberculous therapy which includes rifampicin to assess whether dose escalation of nevirapine is appropriate in this patient population
Conditions
- HIV Infections
- Tuberculosis
Interventions
- DRUG
-
Nevirapine without dose escalation
Fixed dose combination tablets of stavudine 30mg,lamivudine 150mg and nevirapine tablets 200mg twice daily at initiation of antiretroviral therapy in patients receiving rifampicin for tuberculosis therapy
- DRUG
-
Nevirapine initiation with dose escalation
Triomune® 30 (according to body weight) one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
Sponsors & Collaborators
-
University of Liverpool
collaborator OTHER -
Makerere University
lead OTHER
Principal Investigators
-
Concepta A Merry, PhD · University of Dublin, Trinity College
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-05-31
- Primary Completion
- 2009-06-30
- Completion
- 2010-12-31
Countries
- Uganda
Study Locations
More Related Trials
-
Characteristics and Outcomes of TB and HIV Co-infections
NCT06531772 ·Status: RECRUITING
-
Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis
NCT00004736 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Antiretroviral Therapy
NCT02082652 ·Status: COMPLETED ·Phase: PHASE4
-
The Pediatric HIV Nutrition Study in Uganda
NCT02421302 ·Status: UNKNOWN ·Phase: NA
-
Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda
NCT00674921 ·Status: UNKNOWN ·Phase: PHASE4
-
Relationship Between HIV-1 Subtype and ARV Response
NCT00585793 ·Status: COMPLETED
-
Effectiveness of Intensive Adherence Counselling Among People Living With HIV/AIDS With Low-level Viraemia in Uganda.
NCT05514418 ·Status: UNKNOWN ·Phase: NA
-
Safety and Metabolic Study of Highly Active Antiretroviral Therapy (HAART) in Malnourished Children With HIV
NCT01529125 ·Status: COMPLETED
-
Multi-vitamins, HAART and HIV/AIDS in Uganda
NCT01228578 ·Status: COMPLETED ·Phase: PHASE3
-
Vitamin A Therapy for Tuberculosis
NCT00057434 ·Status: COMPLETED ·Phase: PHASE3
-
Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)
NCT01637558 ·Status: COMPLETED ·Phase: PHASE4
-
Tuberculosis in HIV Infected Patients in Uganda
NCT00057421 ·Status: COMPLETED ·Phase: PHASE2
-
Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART
NCT01751646 ·Status: COMPLETED ·Phase: NA
-
Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy
NCT01825031 ·Status: COMPLETED ·Phase: PHASE3
-
Novel Measures and Theory of Pediatric Antiretroviral Therapy Adherence in Uganda
NCT01140633 ·Status: COMPLETED
-
Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
NCT00557245 ·Status: COMPLETED ·Phase: PHASE3
-
Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin
NCT04166474 ·Status: COMPLETED ·Phase: PHASE4
-
Gene Expression in HIV and Tuberculosis Co-infection
NCT01611402 ·Status: COMPLETED
-
Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load
NCT04121195 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Early HIV Therapy in Patients With High CD4 Cell Counts
NCT01479634 ·Status: COMPLETED ·Phase: NA
-
The Effectiveness of a Mobile Interactive Supervised Therapy (MIST) Intervention for Improving Adherence to HIV Medication
NCT03794648 ·Status: COMPLETED ·Phase: NA
-
Rifampin and Efavirenz Interactions in Older Children
NCT01704144 ·Status: UNKNOWN
-
Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa
NCT00640887 ·Status: COMPLETED ·Phase: PHASE2
-
Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment
NCT00737724 ·Status: TERMINATED ·Phase: NA
-
Real-Time Antiretroviral Therapy Adherence Intervention in Uganda
NCT01957865 ·Status: COMPLETED ·Phase: NA